SEC Filing Summary: Prima BioMed Ltd (Form 6-K)
Business Context and Reporting Period
This Form 6-K was filed by Prima BioMed Ltd, a foreign private issuer, on November 21, 2013. The registrant is headquartered in Sydney, New South Wales, Australia. The filing serves to report a specific corporate governance event rather than providing periodic financial results.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notice regarding a change in director interests and does not contain financial statements or performance data.
Material Changes
The material change disclosed in this filing is the submission of an "Appendix 3Y Change of Director's Interest Notice" (Exhibit 99.1). No financial or operational changes relative to a prior comparable period are detailed in this specific document.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, contingencies, or discussion of unusual items. The document is limited to the formal signature by Matthew Lehman, Chief Executive Officer, and the exhibit index.
Key Facts for Investor Verification
- Verify the specific details of the director's interest change referenced in Exhibit 99.1 (Appendix 3Y).
- Confirm the identity of the director whose interest changed, as the summary text only lists the CEO's signature.
- Note that this filing does not update the company's financial position or operational outlook.